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Abstract
Objectives: Dendritic cells (DCs) serve a critical role both in promoting and inhibiting adaptive immunity. The goal of this
study was to investigate the effect of natalizumab (NTZ) treatment on DC numbers, phenotype, and function in patients
with multiple sclerosis (MS).
Methods: Frequency and phenotype of myeloid and plasmacytoid DCs (MDCs and PDCs, respectively) were analyzed in
blood from two separate cohorts of untreated, interferon-treated, or NTZ-treated MS patients. In addition, PDCs were
stimulated with CpG-containing oligonucleotides or co-cultured with homologous T cells in the presence or absence of NTZ
in vitro to determine functional effects of NTZ treatment.
Results: We observed that NTZ treatment was associated with a 25–50% reduction in PDC frequency in peripheral blood as
compared to untreated MS patients, while the frequency of MDCs was unchanged. PDCs in NTZ-treated patients displayed a
mature, activated phenotype with increased expression of HLA-DR, TLR9, CCR7, IL-6 and IL-12. In contrast, in vitro treatment
with NTZ did not increase markers of PDC activation or their ability to induce T cell differentiation.
Conclusion: Our study shows that NTZ treatment is associated with a reduced frequency of PDCs in the peripheral
circulation, but that PDCs in NTZ-treated individuals display an activated phenotype. Taken together the data suggests that
transmigration of activated PDCs is preferentially affected by blockade of integrin a4 leading to an increased frequency of
activated PDCs in blood.
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Introduction
Natalizumab (NTZ) is a humanized monoclonal antibody
(mAb) against the a4 subunit (CD49d) of the a4b1 (VLA-4) and
a4b7 integrins that has been approved for the treatment of
multiple sclerosis (MS) due to its ability to reduce disease activity
and severity in patients with relapsing-remitting MS (RRMS) [1].
NTZ is known to inhibit T cell trafficking to the CNS by blocking
the interactions between VLA-4 on T cells and VCAM-1 on
cerebral endothelial cells, a step that is required for T cell
extravasation to the CNS. Previous studies have shown that NTZ
treatment in MS is associated with increased frequencies of
activated CD4+ T cells producing proinflammatory cytokines such
as IFN-c, TNF, and IL-17 in peripheral blood [2–5]. Such effects
of NTZ are, however, not limited to activated CD4+ T cells, but
an increase in peripheral blood frequencies of total T cells, B cells,
and NK cells has also been demonstrated, while frequencies of
monocytes were decreased [6–9]. In addition to sequestration of
activated cells in the peripheral circulation, these changes in
immune cell composition are believed to be mediated by a higher
release of VLA-4+ hematopoetic precursor cells from the bone
marrow and a decreased retention of memory and marginal zone
B cells within secondary lymphoid organs [3,8,10].
Dendritic cells (DCs) serve a critical role both in promoting and
inhibiting adaptive immunity, depending on the DC subset and
maturation state. Cytokines produced by DCs influence the
differentiation of effector T helper cells into distinct subsets with
unique functions, such as Th1, Th2, Th17, Tr1 or Treg subsets
PLOS ONE | www.plosone.org 1 July 2014 | Volume 9 | Issue 7 | e103716[11]. Integrin a4 is expressed by DCs [12] and preliminary studies
indicate that NTZ treatment in MS is associated with changes in
DC trafficking as evidenced by a potential reduction in the
frequency of circulating plasmacytoid DCs (PDCs) and in the
number of CD209+ DCs in the perivascular spaces of the brain
[13,14]. Antigen-presenting cells (including DCs) in the cerebral
perivascular spaces are believed to be continuously replaced by
cells migrating from peripheral blood and it is plausible that the
observed reduction in DC numbers is due to impaired migration
of DCs from peripheral blood [15,16].
The goal of this study was to investigate the effect of NTZ
treatment on the frequency of circulating DCs, their phenotype,
and ability to induce T cell differentiation or polarization in
patients with MS. Our data showed that NTZ treatment is
associated with reduced frequencies of circulating PDCs and that
PDCs in NTZ treated individuals display an activated phenotype.
Methods
Patients
For our initial studies, we obtained blood from 25 patients with
RRMS treated with NTZ for .1 year (Tysabri, Biogen Idec,
Weston, MA; 300 mg IV every 4 weeks). Twenty-five RRMS
patients treated with IFN-b (Avonex, Biogen Idec; Betaseron,
Bayer Healthcare, Wayne, NJ; Rebif, EMD Serono, Rockland,
MA; all at recommended doses) for .1 year and 25 untreated
RRMS patients were included as controls (cohort 1; Table 1).
Later, we obtained blood from 56 additional RRMS patients to
confirm our findings (cohort 2). Of these, 19 were treated with
NTZ, 16 were treated with IFN-b, and 21 patients were untreated.
Blood from the NTZ-treated patients in cohort 1 was obtained
immediately before an infusion to reflect serum trough levels,
while blood from patients in cohort 2 was obtained at regular
clinical visits regardless of the timing of their NTZ infusions.
Untreated patients had been without any immunomodulatory
treatment for $3 months and had never received any immuno-
suppressive or immunomodulatory medications other than corti-
costeroids, IFN-b, or glatiramer acetate. None of the patients
treated with NTZ or IFN-b had developed neutralizing antibodies
against the drug. Blood for in vitro experiments was obtained from
12 healthy donors (5 women, 7 men; mean age: 30.9 years, range
22–50). The study was approved by the Institutional Review
Board at Brigham and Women’s Hospital (protocol numbers:
2009P002380 and 2001P001431) and all subjects provided written
informed consent.
Isolation of peripheral blood mononuclear cells (PBMCs)
Peripheral blood mononuclear cells (PBMCs) were isolated
through density centrifugation on Ficoll-Paque (GE Healthcare,
Pittsburgh, PA) within two hours of blood collection and used
either fresh or after being cryopreserved in liquid nitrogen
according to the protocols of the Immune Tolerance Network
(www.immunetolerance.org). Frozen samples were thawed and
analyzed in batches containing equal numbers of untreated, NTZ-
and IFN-b-treated patients to reduce batch-to-batch effects. A
quality control sample consisting of PBMCs isolated from a buffy
coat was included in each batch to detect batch-to-batch
variability. Batches with too high variability were excluded from
further analysis.
Frequencies of DCs and their phenotype and gene
expression
Frozen PBMCs were used to determine the frequency of DC
subsets and their expression of cell surface molecules using flow
cytometry. DCs were defined as being negative for hematopoietic
lineage markers (CD3, CD14, CD16, CD19, CD20 and CD56;
Lineage Cocktail 1 (Lin), BD Biosciences, San Jose, CA) and
positive for CD11c (myeloid DCs, MDCs) or CD123 (PDCs). In
addition, all DCs expressed HLA-DR at high levels. Dead cells
were excluded by a viability staining (LIVE/DEAD Fixable Dead
Cell Stain, Invitrogen). Intracellular staining was performed after
fixation and permeabilization (BD Cytofix/Cytoperm, BD Biosci-
ences). Cells were acquired on a BD LSR II flow cytometer (BD
Biosciences) and analyzed using FlowJo (Tree Star, Ashland, OR).
Isotype control antibodies were used to determine background
fluorescence levels.
PDCs and MDCs for gene expression analysis were isolated
from PBMCs using a FACSAria cell sorter (BD Biosciences) using
the same definition as above and were .95% pure. The separated
cells were lysed using RLT buffer (Qiagen, Valencia, CA) and
frozen at 280uC.
Antibodies for flow cytometry
CD4 APC (clone RPA-T4), CD11c APC (B-ly6), CD40 PE
(5C3), CD45 PE (H130), CD49d PE-Cy5 (9F10), CD80 PE
(L307.4), CD83 PE (HB15e), CCR7 PE (150503), Bcl-2 PE (Bcl-2/
100), TLR9 PE (eB72-1665), HLA-DR PE-Cy5 (G46-6), Lineage
Cocktail-1 FITC, and 7-AAD were obtained from BD Biosciences.
CD86 PE-Cy5 (It2.2), and CD123 PE-Cy7 (6H6) were obtained
from BioLegend (San Diego, CA). Polyclonal TLR7 PE was
obtained from Imgenex (San Diego, CA). Bcl-xL PE (H5) was
obtained from St Cruz (Dallas, TX).
In vitro experiments
Purified PDCs isolated from freshly isolated PBMCs were
stimulated with ODN-2006 or 22336 (both at 5 mM; InvivoGen,
San Diego, CA; 10,000 cells/well) for 4 hours in the presence of
15 mg/ml of NTZ or IgG4 (Sigma) after which cells were lysed
using RLT buffer and frozen at 280uC. Freshly isolated PBMCs
were stimulated with ODN-2006 or -2336 (both at 5 mM;
InvivoGen; 500,000 cells/well) for 18 hours in the presence of
15 mg/ml of NTZ or IgG4 (Sigma Aldrich, St Louis, MO). Cells
were retrieved and stained for flow cytometric analysis.
For co-culture experiments, PDCs were isolated from freshly
isolated PBMCs by negative selection using magnetic beads
(Plasmacytoid Dendritic Cell Isolation Kit II, Miltenyi, Auburn,
CA). More than 90% of separated cells were Lin2/CD123+/
CD11c2/HLA-DR+. Cells were stimulated with 5 mM ODN-
2006 for 18 hours (5,000 cells/well). CD4+ T cells were isolated
from homologous blood kept at +4uC overnight by negative
selection using magnetic beads (CD4+ T Cell Isolation Kit II,
Miltenyi) and added to each well (20,000 cells/well). Co-cultures
were incubated for five days in the presence of anti-CD3 (HIT3a,
1 mg/ml, BD Biosciences) and 20U IL-2. Live CD4+ T cells were
isolated by FACS sorting and lysed using RLT buffer.
RNA isolation and real-time PCR
RNA was isolated from frozen cell lysates using Qiagen RNeasy
micro kit (Qiagen). Total RNA was converted to complementary
DNA using Taqman reverse transcription reagents (Applied
Biosystems, Carlsbad, CA). Quantitative PCR was performed
using ViiA 7 Real-Time PCR System (Applied Biosystems). All
primers and probes were obtained from Applied Biosystems and
used according to standard protocols. A comparative threshold
cycle (CT) value was normalized for each sample using the
following formula: DCT=CT(gene of interest)-CT(B2M), and the
relative expression calculated using the formula 2
2DCT.
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Comparisons between NTZ-treated patients and the two
control groups (IFN-treated patients and HC) in all ex vivo
experiments were performed using the non-parametric Mann-
Whitney U-test. MFI values were normalized to the geometrical
mean of each batch (n=5) that contained equal numbers of
donors from each treatment group. Effects of NTZ treatment
in vitro were determined using a paired t-test comparing NTZ-
and isotype-treated cultures from individual donors. The
relation between treatment duration and PDC frequency was
assessed using linear regression. All p-values are two-tailed and
differences were considered statistically significant when p,0.05.
Given the exploratory nature of this study, no corrections for
multiple comparisons were completed. Differences in demo-
graphic characteristics or clinical status between the groups were
determined using ANOVA (age and disease duration), Kruskal-
Wallis one-way analysis of variance (EDSS), or Fisher exact test
(gender and presence of relapses). Statistical analysis was
performed using Prism 6 for Mac OS X (GraphPad Software
Inc., San Diego, CA).
Results
NTZ-treated patients have a decreased frequency of
plasmacytoid DCs in peripheral blood
Patients treated with NTZ had roughly 25% less PDCs in
peripheral blood (0.7260.30%) compared to untreated patients
(1.0460.53%) in our first cohort of 75 patients (p=0.03; Fig. 1A–
B). In order to confirm the results, the frequency of PDCs was
analyzed in a second cohort of 56 patients, which showed an even
more pronounced difference between the groups (NTZ:
0.5060.22%; UNT: 1.0860.59%; p,0.0001; Fig. 1C). There
was no correlation between the frequency of PDCs in NTZ-
treated patients and treatment duration, either in the first
(p=0.21, r
2=0.07) or second cohort (p=0.21, r
2=0.10; Fig. 1D).
There was a decrease in the frequency of PDCs in IFN-b-treated
patients in the first cohort (0.7460.33%; p=0.06), but this was not
statistically significant nor reproduced in the second cohort
(0.9260.67%; p=0.2; Fig. 1B–C). The frequency of MDCs was
not affected by NTZ or IFN-b treatment (Fig. 1A–C).
We confirmed that PDCs express CD49d (integrin a4), a surface
antigen on leukocytes which NTZ binds to, using both flow
cytometry and rt-PCR. Intriguingly, while we observed that the
frequency of CD49d+ PDCs was increased in NTZ-treated
patients, it appeared as the intensity of the CD49d staining
(MFI) was reduced both in the CD49d
hi and CD49d
low
populations and that the total staining intensity of CD49d was
decreased on PDCs from NTZ-treated patients similar to a
previous report [14] (Fig. 2A–E).
PDCs from NTZ-treated patients expressed higher levels of
HLA-DR, CCR7 and Toll-like receptor-9 (TLR9), three markers
associated with cellular activation, maturation and trafficking
abilities in PDCs, compared to untreated patients (Fig. 3A–G),
while the expression of the anti-apoptotic Bcl-2 and Bcl-xL were
comparable in the two groups (data not shown). PDCs isolated
directly ex vivo using FACS sorting of blood from NTZ-treated
patients expressed significantly higher levels of IL-6 and IL-12
(p35) mRNA compared to PDCs isolated from untreated patients
(Fig. 3H–I), while we observed no differences in the expression of
IL-1b, IL-10, IL-23, IL-27 or TGF-b mRNA (data not shown).
We did not observe any changes in the expression of these markers
in PDCs from IFN-b treated patients (Fig. 2, 3); neither was NTZ-
or IFN-b treatment associated with changes in the surface
phenotype or cytokine expression in MDCs (data not shown).
In vitro treatment with NTZ is associated with a slight
decrease in the expression of CD40, CD83, and HLA-DR
mRNA in CpG-stimulated PDCs
PDCs isolated from healthy volunteers were stimulated in vitro
with ODN-2006 or -2336, two synthetic CpG-containing oligo-
nucleotides known to stimulate PDCs [17], in the presence or
absence of NTZ (15 mg/ml). There was a trend towards reduced
expression of CD80 mRNA after NTZ treatment in PDC cultures
stimulated with ODN-2006, a type B ODN known to upregulate
Table 1. Patient demographics.
Untreated Tysabri Interferon p-value
Cohort I
Number of donors 25 (4M/21F) 25 (9M/16F) 25 (6M/19F) p=0.19
Age (years) 41.8 (22–70) 39.1 (23–45) 45.3 (24–65) p=0.15
Disease duration (years) 8.4 (0–33) 9.7 (3–38) 9.0 (2–26) p=0.81
EDSS 1.3 (0–3) 1.8 (0–6.5) 1.6 (0–6) p=0.78
Treatment duration (months) n/a 27.5 (14–42) 70.9 (15–147) n.d.
Relapses within 24 months* 4/14 3/18 5/16 p=0.68
Time to relapse (months) 7.0 (1–20) 12.0 (3–24) 10.4 (1–23) n.d.
Cohort II
Number of donors 21 (1M/20F) 19 (3M/16F) 16 (3M/13F) p=0.33
Age (years) 43.4 (22–64) 42.9 (26–56) 46.8 (30–62) p=0.45
Disease duration (years) 9.8 (0–20) 8.8 (2–22) 9.4 (4–18) p=0.82
EDSS 1.1 (0–6) 1.7 (0–6) 1.6 (0–3) p=0.11
Treatment duration (months) n/a 31.4 (5–55) 54.4 (5–127) n.d.
*Number of donors with a documented relapse during 24 months of follow-up. M=male; F=female. Data is expressed as mean (range) unless otherwise specified.
EDSS=Expanded Disability Status Scale. Differences between the groups were determined using ANOVA (age and disease duration), Kruskal-Wallis one-way analysis of
variance (EDSS), or Fisher exact test (gender and presence of relapses; p-value shows comparison Untreated vs. Tysabri).
doi:10.1371/journal.pone.0103716.t001
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3.5362.45; Isotype: 4.4562.76; p=0.054; n=7) [18]. In vitro
treatment with NTZ did not affect CD80 mRNA expression in
cultures stimulated with ODN-2336, a type A ODN that induces
large amounts of IFN-a by PDCs [19], nor did it result in
increased expression of CD49d, HLA-DR, TLR9, CCR7, IL-6, or
IL-12 mRNA in PDCs, as observed ex vivo in NTZ-treated MS
patients, either when PDCs were stimulated with ODN-2006 or -
2336 (Fig. 4A).
It is plausible that the lack of effects of NTZ on PDCs in pure
PDC cultures is reflecting that NTZ modulates PDCs indirectly
through factors secreted from other cells present in peripheral
blood. In order to simulate this, we stimulated total PBMCs with
ODN-2006 or -2336 in the presence or absence of NTZ and
Figure 1. Frequency of myeloid and plasmacytoid dendritic cells in peripheral blood. Frequency of myeloid and plasmacytoid dendritic
cells (MDCs and PDCs) was determined in frozen cells from relapsing-remitting MS patients using flow cytometry. A. Dead cells were excluded using a
viability dye (LIVE/DEAD), followed by exclusion of cells expressing mature hematopoietic lineages using a Lineage cocktail (CQ). PDCs and MDCs
were identified based on their expression of CD123 and CD11c, respectively. B–C. Frequency of MDCs and PDCs in untreated MS patients (UNT) and
MS patients treated with natalizumab (NTZ) or interferon-b (IFN) from Cohort 1 (B) and Cohort 2 (C). Graph shows mean, interquartile range, and min-
max range. Frequency of PDCs in NTZ-treated patients in relation to duration of treatment in patients from Cohort 1 (filled) or Cohort 2 (open) (D).
doi:10.1371/journal.pone.0103716.g001
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CCR7, and HLA-DR in PDCs using flow cytometry. NTZ
treatment of PBMCs did not change the frequency or viability of
PDCs (data not shown). Contrary to the findings ex vivo, we
observed a statistically significant decrease in CD40 expression in
ODN-2006 stimulated cultures (NTZ: 23.81622.24; Isotype:
27.20623.80; p=0.028; Fig. 4B) and a trend towards decreased
CD40 expression in ODN-2336 stimulated cultures (NTZ:
15.77620.65; Isotype: 21.64628.36; p=0.22; Fig. 4B). In addi-
tion, the expression of CD83 and HLA-DR were decreased after
NTZ treatment in ODN-2336 stimulated cultures (NTZ:
33.64618.93; Isotype: 38.74619.15; p=0.001; and NTZ:
35.89618.47; Isotype: 39.18618.33; p=0.037; respectively;
Fig. 4B).
NTZ effects on the functional ability of PDCs to stimulate
CD4 cell responses
In order to address if NTZ has any effects on the functional
ability of PDCs to stimulate CD4+ T cell responses, we isolated
PDCs from healthy volunteers, stimulated them with ODN-2006
in the presence or absence of NTZ, co-cultured them with purified
homologous CD4+ T cells, and determined cytokine mRNA
expression in CD4+ T cells using rt-PCR. Under the conditions
used, we could not demonstrate any changes in the mRNA
expression of a panel of cytokines and transcription factors selected
to reflect Th1/Th2/Th17/T reg differentiation in CD4+ T cells
(IL-4, IL-9, IL-10, IL-13, IL-17, IFN-c, TGF-b, RORct, T bet,
GATA-3, STAT6, and Foxp3; Fig. 5).
Discussion
In this study, we observed that the frequency of PDCs was 25–
50% lower in blood from NTZ-treated compared to untreated MS
patients in two separate cohorts. Interestingly, the decrease seemed
to be dose-dependent as a more pronounced decrease was
observed in patients analyzed at clinical visits unrelated in time
to the infusions than in patients analyzed at the end of a dosing
interval, immediately before an infusion. This is consistent with a
small study of six patients followed for one year after initiation of
NTZ therapy, which previously reported a non-statistically
significant decrease in PDCs [14]. We did not see any effect of
treatment duration, which ranged from 5–55 months, on PDC
frequency. The effects of NTZ on lymphocyte numbers are known
to occur within the first months of treatment and remain persistent
for treatment durations of 2–3 years [8,20,21].
As NTZ treatment is known to increase the numbers of
multiple lymphocyte subsets in peripheral blood [6–8,22], we
Figure 2. CD49d expression on plasmacytoid dendritic cells. Mean fluorescence intensity (MFI) of CD49d on plasmacytoid dendritic cells
(PDCs)(A) and frequency of PDCs expressing CD49d (B), in peripheral blood from untreated MS patients (UNT) and MS patients treated with
natalizumab (NTZ) or interferon-b (IFN) determined by flow cytometry. Box-and-whisker plots showing mean, interquartile range, and min-max range.
Representative histograms showing CD49d staining on PDCs from an UNT (blue open; C, E) and a NTZ-treated (red filled; D, E) patient.
doi:10.1371/journal.pone.0103716.g002
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the circulation during NTZ treatment [2–4]. We calculated the
frequency of PDCs in total live PBMCs and it is possible that
the decrease in PDC frequency is reflecting an increase in other
lymphocyte subsets during NZT treatment rather than a
decrease in PDC numbers per se [22]. MDCs are present at
comparable levels to PDCs in peripheral blood but unlike PDCs
the frequency of MDCs did not decrease after NTZ treatment.
The frequency of MDCs could be considered an internal
control for any change in total lymphocyte counts. Myeloid cells
express CD49d, but NTZ treatment does not seem to affect
numbers and/or frequencies of monocytes or MDCs
[6,7,14,21,23]. Thus, we would suggest that the decrease in
PDC frequency in NTZ-treated subjects is specific and not
merely related to changes in other cell populations.
The observed reduction in PDC frequency in blood may
reflect a general decrease in CNS inflammation following NTZ
treatment resulting in reduced PDC mobilization. Resting PDCs
can under inflammatory conditions enter peripheral tissues,
respond to the local environment, and become activated.
Activated PDCs may then acquire antigen and return to
secondary lymphoid organs [24]. In contrast to other DC
populations, PDCs do not migrate to secondary lymphoid
organs through afferent lymphatic vessels, but through the blood
stream [25]. Interestingly, we observed that while the frequency
of PDCs were decreased in NTZ-treated patients, the cells
detected displayed a phenotype consistent with activated,
mature PDCs, characterized by increased expression of HLA-
DR, TLR9, CCR7, IL-6 and IL-12, which would argue that
additional factors besides less CNS inflammation contribute to
the changes is PDC frequency and phenotype.
Figure 3. Phenotype and cytokine expression of plasmacytoid dendritic cells. Frequency of plasmacytoid dendritic cells (PDCs) expressing
TLR9 (A), HLA-DR (B), and CCR7 (C) in peripheral blood from untreated MS patients (UNT) and MS patients treated with natalizumab (NTZ) or
interferon-b (IFN) determined using flow cytometry. Representative histograms showing TLR9 (D) and HLA-DR (E), staining on PDCs from an UNT
(blue open) and a NTZ-treated (red filled) patient. Flow plots showing CCR7 staining on CD49d
hi and CD49d
low PDCs from an UNT (F) and a NTZ-
treated (G) patient. Expression of IL-6 (H) and IL-12 (p35) (I) mRNA in PDCs isolated from the patients described in A-C using FACS sorting and rt-PCR
without ex-vivo stimulation. Graph shows mean, interquartile range, and min-max range (A–C) or mean and SD (H–I).
doi:10.1371/journal.pone.0103716.g003
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has been shown to follow the same multi-step procedure of
tethering, rolling, adhesion, and transmigration as has been
described for T cells [26]. Blocking experiments have shown that
integrins, including both the a4 and the b1 subunits of VLA-4, are
involved in the attraction of PDCs to endothelial cells both in
secondary lymphoid organs and peripheral tissue [27–29]. We
observed the seemingly contradictory finding that NTZ-treated
patients had a higher frequency of CD49d+ PDCs, but that the
staining intensity of each cell was lower, indicating less CD49d
molecules on the cell surface. The staining intensity of CD49d has
previously been shown to be reduced on most lymphocyte subsets,
including PDCs, during NTZ treatment presumably due to
internalization and/or shredding [5,14,23]. On the other hand,
integrin a4 is upregulated on DCs upon maturation [12]
consistent with the increased expression of other markers for
activated, mature PDCs in NTZ-treated patients in our study. It is
possible, although speculative, that mature PDCs with their higher
expression of CD49d are more dependent on VLA-4 mediated
adhesion than immature PDCs. This could result in relatively
more efficient blockade of the migration of activated PDCs to
lymphatic tissue compared to the migration of resting PDCs to
inflamed tissue, leading to an increased frequency of activated
PDCs in the peripheral circulation. Further in vitro experiments
with chemotaxis assays would be needed to fully understand
differences in trafficking behavior between activated and resting
PDCs.
We did not find any evidence indicating that NTZ treatment
would result in direct PDC activation during in vitro experiments
using PDCs stimulated with synthetic CpG-containing oligonu-
cleotides. In contrast, we observed a slight decrease in the
expression of CD40, CD83 and HLA-DR on these cells. This is in
agreement with a previous study showing reduced ability of NTZ-
treated PDCs to stimulate PPD-specific CD4+ T cell proliferation
[14]. It is likely that this discrepancy between in vivo and in vitro
effects of NTZ reflects effects of NTZ on PDC trafficking behavior
rather than direct effects on the activation or maturation of the
cells. Although VLA-4 cross-linking has been associated with
tyrosine phosphorylation and T cell costimulation [30], studies on
T cells have shown little evidence that NTZ exerts a direct effect
on cellular activation or maturation [3–5,31]. This mechanism of
action differs from other therapies in MS with effects on PDCs,
such as IFN-b treatment, which has been shown to directly affect
PDCs during in vitro stimulation resulting in reduced proinflam-
Figure 4. In vitro effects of natalizumab treatment on plasmacytoid dendritic cells. Effects of natalizumab (NTZ) treatment on
plasmacytoid dendritic cells (PDCs) stimulated in vitro with CpG-containing oligonucleotides (open: ODN-2006; gray: ODN-2336). (A) PDCs were
isolated from healthy controls using FACS sorting and stimulated in the presence of 15 mg/ml of NTZ or an isotype control for 4 hours. The expression
of CD49d, IL-6, IL-12 (p35), TNF, TLR9, CD80, HLA-DR, and CCR7 mRNA was determined using rt-PCR. (B) Total PBMCs were stimulated in the presence
of 15 mg/ml of NTZ or an isotype control for 18 hours. Surface expression of CD49d, CD40, CD80, CD83, CD86, CCR7, and HLA-DR was determined on
PDCs using flow cytometry. Graphs shows fold change in expression comparing cultures treated with NTZ to cultures treated with an isotype control.
doi:10.1371/journal.pone.0103716.g004
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expression of programmed death ligand 1 (PD-L1), and increased
IL-10 secretion [32].
PDCs are key regulators in the development of both innate and
adaptive immune responses. They have the ability to quickly
respond to viral antigens by secreting large amounts of type I
interferons [33], but they also upregulate the expression of MHC
class II and costimulatory molecules upon maturation, enabling
them to engage in antigen presentation and T cell activation [34].
Depending on the localization and the specific microenvironment,
PDCs may have both immunogenic and tolerogenic functions
[35]. We performed co-culture experiments to determine the
functional ability of NTZ-treated PDCs to stimulate CD4 cell
responses in vitro. Although the small number of donors analyzed
precludes finding any minor differences, our data did not
demonstrate any large effects of NTZ on PDCs ability to affect
Th1/Th2/Th17/T reg differentiation in vitro.
A caveat when interpreting the results of this study is its cross-
sectional design. It is possible that the observed differences in PDC
frequency and activation are caused by differences between the
groups rather than the treatment per se. However, there were no
differences in demographics, disease duration, or EDSS between
the NTZ-treated and untreated patients. While it is possible that
untreated patients are untreated due to a milder disease, other
reasons for patients to be untreated include being newly
diagnosed, undergoing a wash-out period between treatments,
trying to become pregnant, having a fear of side effects, or fear of
medical treatment. There was no evidence for milder disease in
the untreated patients in Cohort I for which we had two years of
prospective follow-up, but a trend towards a higher relapse-rate
and shorter time to first relapse.
In conclusion, our study shows that NTZ-treated MS patients
have decreased frequencies of PDCs in peripheral blood, but that
the PDCs remaining in blood display a phenotype consistent with
activated mature PDCs. Taken together, the data suggests that
NTZ has a differential effect on the migration of activated PDCs
to lymphoid tissue resulting in increased frequencies of activated
PDCs in blood. Further studies are needed to determine the
functional relevance of this finding. As PDCs are important
regulators of both innate and adaptive immune responses, capable
of inducing both immunogenic and tolerogenic responses,
pharmacological manipulation of their numbers or state of
activation may have significant effects on the course of the disease
being treated.
Figure 5. Effects of natalizumab treatment on plasmacytoid dendritic cells function. Effects of natalizumab (NTZ) treatment on the
functional ability of plasmacytoid dendritic cells (PDCs) to stimulate CD4 cell responses. PDCs were isolated from healthy controls using FACS sorting
and stimulated with ODN-2006 for 18 hours in the presence of 15 mg/ml of NTZ or an isotype control and homologous CD4+ T cells were added.
CD4+ T cells were isolated after an additional 6 days of incubation and cytokine mRNA expression determined using rt-PCR. Graph shows expression
in cultures treated with NTZ or an isotype.
doi:10.1371/journal.pone.0103716.g005
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